How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

    The content on this page is not current guidance and is only for the purposes of the consultation process.

    Validity and generalisability of the studies

    • Studies were done in Canada and Germany. There was no data related to the UK context.

    • The total sample was small (n=62). Bozso (2021) had the longest follow-up period (median 631 days; outcomes were reported at 1 year after operation), and Montagner (2021) had the shortest follow-up duration (perioperative period). Therefore, studies in larger cohorts with longer follow-up were lacking.

    • All patients had ATAD I but there was variation in the inclusion criteria, such as patients with ATAD I complicated by malperfusion or patients presenting with ATAD I and affected SAVs.

    • One device (AMDS) was used, and its insertion was done during hemiarch repair in all patients but one (who had total arch replacement).